Your session is about to expire
← Back to Search
Upifitamab Rilsodotin for Cancer
Study Summary
This trial is testing the safety of a new antibody-drug conjugate (ADC) called XMT-1536 in patients with various types of cancer. The ADC will be administered as an IV infusion every 4 weeks. This study will also assess the ADC's activity and how it is metabolized by the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition did not improve with platinum-based chemotherapy.My heart rate is between 45 and 100, and I don't have a normal heart rhythm.I have had 1 to 4 treatments for ovarian cancer.All side effects from my previous treatments are mild, except for hair loss or stable conditions I'm being treated for.I am not taking medication that strongly affects liver enzyme activity.I have a heart valve problem that is more than moderate.I have high-grade serous ovarian, fallopian tube, or peritoneal cancer that has spread or come back.I have had bevacizumab as part of my first or second line of treatment.My tumor is a specific type, such as low-grade, clear cell, or others listed.My cancer did not respond to platinum-based chemotherapy.I have an eye condition affecting the cornea or had one in the past year.I am taking medication that strongly affects liver enzyme levels and cannot stop while on the study treatment.I haven't had cancer in the last 2 years, except for certain skin cancers or cervical cancer that were treated.I have a history of liver disease.I do not have any severe illnesses that could affect my trial participation.I have had lung inflammation or scarring.I have previously been treated with a drug similar to mirvetuximab soravtansine.I have brain metastases that haven't been treated or a history of cancer spreading to my brain's lining.I haven't had major surgery or cancer treatment recently.I do not have an active infection with HIV, hepatitis B, or hepatitis C.I am willing to provide a sample of my tumor for testing.I am fully active or can carry out light work.I use oxygen therapy regularly.My blood tests and kidney function are within normal ranges, and I can make my own medical decisions.My heart does not have uncontrolled irregular rhythms.
- Group 1: Dose Escalation
- Group 2: Dose Expansion - Ovarian Cancer
- Group 3: Dose Expansion - NSCLC adenocarcinoma
- Group 4: Pivotal Cohort (UPLIFT)
- Group 5: QTc Sub-Study
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what regions is the research effort currently being conducted?
"This experiment is taking place in 15 various facilities, including Texas Oncology-Fort Worth Cancer Center (Fort Worth), VCU Massey Cancer Centre (Richmond) and Henry Ford Medical Centre (Detroit). The other sites are under wraps."
Are there still openings available for participants in this clinical experiment?
"According to research published on clinicaltrials.gov, this medical experiment is in the process of recruiting patients who meet its criteria. The trial was first launched on December 12th 2017 and recently revised on October 18th 2022."
To what extent is the public participating in this clinical experiment?
"This clinical trial requires 444 qualified patients to participate. They can access the treatment at Texas Oncology-Fort Worth Cancer Center in Fort Worth, Texas and VCU Massey Cancer Center in Richmond, Virginia."
What goals is this trial attempting to reach?
"The primary aim of this medical research, which will be tracked over a maximum period of 24 months or until disease progression is documented, focuses on determining the anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin). Secondary objectives include analyzing the confirmed investigator-assessed objective response rate regardless of NaPi2b expression, monitoring tumor size to determine anti-neoplastic impacts, and assessing IRR for patients with high NaPi2b levels as well as overall."
Share this study with friends
Copy Link
Messenger